KOBE Biomedical Innovation Cluster newsletter vol.9
- March 2021 -
vol.9 March 2021
Hello, It is getting warmer little by little. Around this time of the year, "Cherry Blossom Forecast" is broadcasted everyday, which tells us when cherry will bloom in different areas within Japan. Cheery blossoms are like a symbol of coming of spring for Japanese people, and many of us pay attention to the forecast. Since Japan stretches from northernmost island Hokkaido to the south, down into Okinawa, the start of flowering season differs from place to place. In fact, southern part of Japan are already in bloom, and according to the latest forecast, it will start blooming in Kobe in about a week or so 🌸 Can't really wait!
This is our 9th issue of KBIC Newsletter. If you missed any of our past issues, please visit e-newsletter archive page (https://www.fbri-kobe.org/kbic/english/newsletter/)and catch up with our latest activities.
FBRI Editorial Team
Carna Bioscience, Inc. announced completion of PMDA review for a clinical trial notification to initiate clinical trial of AS-0141
(Published: February 22, 2021)
Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces today that the Pharmaceuticals and Medical Devices Agency (PMDA) review for the clinical trial notification of AS-0141 to initiate phase I study in solid tumors has been successfully completed.
JCR Pharmaceuticals Co., Ltd. Decided to Construct a New Plant for COVID-19 Vaccine Solution
(Published: March 4, 2021)
JCR Pharmaceuticals Co., Ltd. announced that it has decided to construct a new plant for the manufacturing of the COVID-19 vaccine solution. A notarial deed and sale agreement for a parcel owned by the City of Kobe has been concluded.
Kobe City, Rakuten Medical Japan and Kobe University to collaborate on research and development of new cancer treatments based on the Illuminox™ platform
(Published: February 9, 2020)
Kobe City, Rakuten Medical Japan K.K., a wholly owned subsidiary of RAKUTEN Medical, Inc., and Kobe University Graduate School of Medicine have concluded a 3-way agreement to jointly conduct research and development for new treatments for cancer based on the Illuminox™ platform at Kobe Biomedical Innovation Cluster.
Entry into the Japanese Biomedical Market Through the City of Kobe
Date/Time: March 23, 2021 5:30pm ~ 7:00pm (JST)
Fee: Free of Charge
Due to the corona pandemic, international cooperation in the field of biomedical technology has become even more important. Kobe has had good experience with European companies for a long time. On this basis, the cooperation is now to be accelerated and expanded. The city offers many advantages in terms of size, location, environment and economic strength.
In addition, there are special programs and funding measures that make getting started in Japan much easier. Japan's largest research and development hub for biomedicine with 370 companies is located on the artificial island Port Island. This results in ideal opportunities for cooperation and exchange.
With this in mind, we would like to cordially invite you to our virtual event together with the Kobe Business Offensive, Foundation for Biomedical Research and Innovation at Kobe (FBRI) and Dürr Dental Japan K.K.